Literature DB >> 29276248

Letter to the Editor on "Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options".

Jennifer Ibrahim1, Rebecca Call2.   

Abstract

Year:  2017        PMID： 29276248      PMCID： PMC5735765          DOI： 10.1177/0018578717735641

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  16 in total

1.  The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.

Authors:  J Charrow; H C Andersson; P Kaplan; E H Kolodny; P Mistry; G Pastores; B E Rosenbloom; C R Scott; R S Wappner; N J Weinreb; A Zimran
Journal:  Arch Intern Med       Date:  2000-10-09

2.  Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.

Authors:  Annalisa Sechi; Laura Deroma; Andrea Dardis; Giovanni Ciana; Nicole Bertin; Daniela Concolino; Silvia Linari; Chiara Perria; Bruno Bembi
Journal:  Mol Genet Metab       Date:  2014-08-04       Impact factor: 4.797

3.  Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.

Authors:  Pramod K Mistry; Elena Lukina; Hadhami Ben Turkia; Dominick Amato; Hagit Baris; Majed Dasouki; Marwan Ghosn; Atul Mehta; Seymour Packman; Gregory Pastores; Milan Petakov; Sarit Assouline; Manisha Balwani; Sumita Danda; Evgueniy Hadjiev; Andres Ortega; Suma Shankar; Maria Helena Solano; Leorah Ross; Jennifer Angell; M Judith Peterschmitt
Journal:  JAMA       Date:  2015-02-17       Impact factor: 56.272

Review 4.  The management of pregnancy in Gaucher disease.

Authors:  Sorina Granovsky-Grisaru; Nadia Belmatoug; Stephan vom Dahl; Eugen Mengel; Elizabeth Morris; Ari Zimran
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2011-01-26       Impact factor: 2.435

5.  Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options.

Authors:  Alison Van Rossum; Megan Holsopple
Journal:  Hosp Pharm       Date:  2016-07

6.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Authors:  J K Hicks; K Sangkuhl; J J Swen; V L Ellingrod; D J Müller; K Shimoda; J R Bishop; E D Kharasch; T C Skaar; A Gaedigk; H M Dunnenberger; T E Klein; K E Caudle; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2017-02-13       Impact factor: 6.875

7.  Life expectancy in Gaucher disease type 1.

Authors:  Neal J Weinreb; Patrick Deegan; Katherine A Kacena; Pramod Mistry; Gregory M Pastores; Priscilla Velentgas; Stephan vom Dahl
Journal:  Am J Hematol       Date:  2008-12       Impact factor: 10.047

Review 8.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

9.  Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.

Authors:  Timothy M Cox; Guillermo Drelichman; Renata Cravo; Manisha Balwani; Thomas Andrew Burrow; Ana Maria Martins; Elena Lukina; Barry Rosenbloom; Ozlem Goker-Alpan; Nora Watman; Amal El-Beshlawy; Priya S Kishnani; Maria Lucia Pedroso; Sebastiaan J M Gaemers; Regina Tayag; M Judith Peterschmitt
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113

10.  Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.

Authors:  Timothy M Cox; Guillermo Drelichman; Renata Cravo; Manisha Balwani; Thomas Andrew Burrow; Ana Maria Martins; Elena Lukina; Barry Rosenbloom; Leorah Ross; Jennifer Angell; Ana Cristina Puga
Journal:  Lancet       Date:  2015-03-26       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.